The FDA has approved Dupixent for the treatment of prurigo nodularis in adults, Regeneron and Sanofi announced in a press release.
Dupixent (dupilumab), given as a subcutaneous injection, is the first drug approved by the FDA for this indication.
Prurigo nodularis, a chronic debilitating inflammatory skin disease that causes extreme quality of life disruptions, affects approximately 75,000 adults in the United States.
“Until today, there were limited treatment options to manage the relentless itch and associated sensations of burning and stinging skin that can negatively impact the lives